Brokerages Set AdaptHealth Corp. (NASDAQ:AHCO) Price Target at $14.14

AdaptHealth Corp. (NASDAQ:AHCO) has received a consensus rating of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $14.1429.

AHCO has been the topic of several recent research reports. Truist Financial upped their price objective on AdaptHealth from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Robert W. Baird cut their target price on shares of AdaptHealth from $18.00 to $15.00 and set an “outperform” rating for the company in a report on Monday, July 6th. Wall Street Zen upgraded shares of AdaptHealth from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Weiss Ratings reissued a “sell (d)” rating on shares of AdaptHealth in a report on Friday, May 22nd. Finally, Jefferies Financial Group raised shares of AdaptHealth from a “hold” rating to a “buy” rating and increased their price target for the stock from $11.00 to $13.00 in a report on Tuesday, July 21st.

Insider Buying and Selling at AdaptHealth

In other news, insider Russell E. Schuster III sold 11,275 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $10.06, for a total transaction of $113,426.50. Following the sale, the insider directly owned 136,538 shares of the company’s stock, valued at $1,373,572.28. This represents a 7.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.95% of the company’s stock.

Hedge Funds Weigh In On AdaptHealth

Institutional investors and hedge funds have recently modified their holdings of the business. Handelsbanken Fonder AB purchased a new position in AdaptHealth during the second quarter worth approximately $226,000. Empowered Funds LLC increased its position in shares of AdaptHealth by 1.4% in the first quarter. Empowered Funds LLC now owns 622,904 shares of the company’s stock valued at $7,413,000 after buying an additional 8,602 shares in the last quarter. Quantinno Capital Management LP raised its stake in shares of AdaptHealth by 140.0% during the 1st quarter. Quantinno Capital Management LP now owns 109,694 shares of the company’s stock worth $1,305,000 after buying an additional 63,992 shares during the period. Lazard Asset Management LLC raised its stake in shares of AdaptHealth by 35.0% during the 1st quarter. Lazard Asset Management LLC now owns 1,669,454 shares of the company’s stock worth $19,867,000 after buying an additional 432,664 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of AdaptHealth by 10.1% during the 1st quarter. Renaissance Technologies LLC now owns 228,373 shares of the company’s stock valued at $2,718,000 after buying an additional 21,000 shares in the last quarter. Hedge funds and other institutional investors own 82.67% of the company’s stock.

AdaptHealth Stock Up 1.9%

Shares of AHCO opened at $10.96 on Friday. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -17.68, a PEG ratio of 0.55 and a beta of 1.45. AdaptHealth has a 52 week low of $8.51 and a 52 week high of $13.43. The stock’s 50-day moving average price is $10.25 and its 200-day moving average price is $10.67. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 1.21.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.